Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,153 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions.
Major A, Yu J, Shukla N, Che Y, Karrison TG, Treitman R, Kamdar MK, Haverkos BM, Godfrey J, Babcook MA, Voorhees TJ, Carlson S, Gaut D, Oliai C, Romancik JT, Winter AM, Hill BT, Bansal R, Villasboas Bisneto JC, Nizamuddin IA, Karmali R, Fitzgerald LA, Stephens DM, Pophali PA, Trabolsi A, Schatz JH, Hu M, Bachanova V, Slade MJ, Singh N, Ahmed N, McGuirk JP, Bishop MR, Riedell PA, Kline J. Major A, et al. Among authors: kline j. Blood Adv. 2023 Aug 22;7(16):4528-4538. doi: 10.1182/bloodadvances.2023010016. Blood Adv. 2023. PMID: 37026796 Free PMC article.
Update on checkpoint blockade therapy for lymphoma.
Kline J, Bishop MR. Kline J, et al. J Immunother Cancer. 2015 Jul 21;3:33. doi: 10.1186/s40425-015-0079-8. eCollection 2015. J Immunother Cancer. 2015. PMID: 26199729 Free PMC article.
Emerging role of checkpoint blockade therapy in lymphoma.
Galanina N, Kline J, Bishop MR. Galanina N, et al. Among authors: kline j. Ther Adv Hematol. 2017 Feb;8(2):81-90. doi: 10.1177/2040620716673787. Epub 2017 Jan 22. Ther Adv Hematol. 2017. PMID: 28203344 Free PMC article. Review.
Mechanisms of Immune Tolerance in Leukemia and Lymphoma.
Curran EK, Godfrey J, Kline J. Curran EK, et al. Among authors: kline j. Trends Immunol. 2017 Jul;38(7):513-525. doi: 10.1016/j.it.2017.04.004. Epub 2017 May 13. Trends Immunol. 2017. PMID: 28511816 Free PMC article. Review.
Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation for High-Risk Lymphoma and Chronic Lymphoblastic Leukemia.
Hsu J, Artz A, Mayer SA, Guarner D, Bishop MR, Reich-Slotky R, Smith SM, Greenberg J, Kline J, Ferrante R, Phillips AA, Gergis U, Liu H, Stock W, Cushing M, Shore TB, van Besien K. Hsu J, et al. Among authors: kline j. Biol Blood Marrow Transplant. 2018 Feb;24(2):359-365. doi: 10.1016/j.bbmt.2017.10.040. Epub 2017 Nov 8. Biol Blood Marrow Transplant. 2018. PMID: 29128555 Free PMC article.
Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older Adults.
Tsai SB, Rhodes J, Liu H, Shore T, Bishop M, Cushing MM, Gergis U, Godley L, Kline J, Larson RA, Mayer S, Odenike O, Stock W, Wickrema A, van Besien K, Artz AS. Tsai SB, et al. Among authors: kline j. Biol Blood Marrow Transplant. 2018 May;24(5):997-1004. doi: 10.1016/j.bbmt.2017.12.794. Epub 2017 Dec 27. Biol Blood Marrow Transplant. 2018. PMID: 29288821 Free article.
Outcomes following second allogeneic stem cell transplant for disease relapse after T cell depleted transplant correlate with remission status and remission duration after the first transplant.
Fan Y, Artz AS, van Besien K, Stock W, Larson RA, Odenike O, Godley LA, Kline J, Cunningham JM, LaBelle JL, Bishop MR, Liu H. Fan Y, et al. Among authors: kline j. Exp Hematol Oncol. 2019 Jan 3;8:1. doi: 10.1186/s40164-018-0125-6. eCollection 2019. Exp Hematol Oncol. 2019. PMID: 30622841 Free PMC article.
1,153 results